Skip to content
Parakho

Cohance Lifesciences Ltd

NSE COHANCEBSE 543064

Q1 FY27, unaudited

Revenue
₹422.26 Cr
Profit after tax
₹-45.19 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations422.26−23.13%2,268.55
Other income12.25−13.55%34.09
Total income434.51−22.89%2,302.64
Employee benefit expense132.96−0.27%507.71
Finance costs6.74−33.79%37.24
Depreciation & amortisation49.54+9.75%187.33
Total expenses477.38−3.09%2,066.13
Profit before tax-42.87−168.31%207.04
Tax expense2.32−85.82%56.92
Profit after tax-45.19−197.39%150.12
Total comprehensive income-39.40−185.02%249.16
Earnings per share
Earnings per share, basic₹-0.63₹4.69
Earnings per share, diluted₹-0.65₹4.68

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — unaudited, from the company’s filing with NSE. Source

Earnings call

Q4 FY26

Cohance Lifesciences reported FY26 revenue of INR22.68 billion, down approximately 13% year-on-year, with adjusted EBITDA of INR4.77 billion and an EBITDA margin of 21%. Management attributed the decline to destocking in two large commercial CDMO molecules, product-specific and shipment issues in API+, and a temporary disruption at the Nacharam formulation site. Management said Q1 FY27 would be weak on revenue and EBITDA, with growth returning from the second half of FY27 as order books convert into shipments.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Filings

12 shown · 46 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 13 Aug 2026.

Cohance Lifesciences Ltd (COHANCE) — filings and results · Parakho